IA
CRSP icon

IFG Advisory’s CRISPR Therapeutics CRSP Stock Holding History

IFG Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.1K Buy
+661
New +$34.8K ﹤0.01% 1441
2021
Q3 		– Sell
-7,223
Closed -$1.17M – 483
2021
Q2 		$1.17M Buy
+7,223
New +$878K 0.13% 183

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IFG Advisory's CRSP Position: Q2 2026 in Review

IFG Advisory opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 661 shares worth $36.1K. The stake represents ﹤0.01% of the portfolio and ranks #1441 among its holdings. This is a return to the name: IFG Advisory previously reported a position in CRSP as recently as Q2 2021.

IFG Advisory first reported a position in CRSP in Q2 2021 and has held it in 2 quarters since. The position peaked at $1.17M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • IFG Advisory held 661 shares of CRISPR Therapeutics worth $36.1K as of Q2 2026.
  • CRISPR Therapeutics was a new IFG Advisory position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1441 holding.
  • IFG Advisory first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • IFG Advisory's CRISPR Therapeutics position peaked at $1.17M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.